Abstract
Background: Studies show inconsistent results regarding the relationship between Helicobacter pylori (H. pylori) infection and stroke. The present study assessed a potential association between H. pylori infection and an important risk factor for stroke, intracranial atherosclerosis.
Methods: In total, 15,798 subjects with transcranial Doppler (TCD) and 13C-urea breath test (13C-UBT) were enrolled from March 2012 to March 2017. Intracranial atherosclerosis was further measured using intracranial carotid artery calcification (ICAC) on past or recent head CT, and 14,084 subjects were ultimately included in the study. Baseline demographics, atherosclerosis risk factors, and laboratory results were investigated. Since endothelial dysfunction is critical to the development of atherosclerosis, the role of H. pylori in migration, tube formation, and proliferation of human brain microvascular endothelial cells (HBMECs) was assessed in vitro.
Results: The intracranial atherosclerosis group had a higher proportion of women and a greater rate of H. pylori infection than those without intracranial atherosclerosis. H. pylori infection was significantly more common in women with intracranial atherosclerosis than males. In addition, the incidence of intracranial atherosclerosis was significantly higher in women with H. pylori infection than uninfected women (53.8 vs. 46.4%, p < 0.001). In an adjusted model, H. pylori was shown to be an independent risk factor for intracranial atherosclerosis in women ≤ 60 years of age [odds ratio (OR) = 2.261, 95% CI = 1.839–2.780, p < 0.001]. Serum exosomes from patients with H. pylori infection had significantly reduced brain endothelial cell migration, tube formation, and proliferation in vitro.
Conclusion:Helicobacter pylori infection may be an important independent risk factor for intracranial atherosclerosis in women ≤ 60 years of age.
Introduction
Helicobacter pylori (H. pylori), a microaerophilic bacterium that colonizes the human gastric epithelium, is the causative agent for one of the most common bacterial infections worldwide (). The prevalence of H. pylori ranges from 30 to 50% in developed countries to ~80% in developing countries, especially those in Asia, as a result of differences in environmental factors, individual lifestyle, and population-based characteristics (–). H. pylori is well recognized as the primary pathogen involved in peptic ulcer, chronic gastritis, and gastric cancer () and has been more recently associated with many non-gastrointestinal diseases, such as cardiovascular, neurological, hematological, metabolic, and skin disorders (, ).
Intracranial atherosclerosis is defined by wall thickening, non-stenosing plaques, or luminal narrowing of the intracranial arteries that can lead to transient or permanent cerebral ischemic events and is considered the major risk factor for stroke (, ). Age, arterial hypertension, type 2 diabetes mellitus (T2DM), and metabolic syndrome are the conventional risk factors for atherosclerosis (, ). However, studies indicate that 30–50% of patients lack these risk factors, suggesting that other factors influence pathogenesis (). In addition, because atherosclerosis is a chronic inflammatory disease, ongoing chronic infection may impact disease development (). Several studies have shown an association between H. pylori infection and stroke (–). A systematic review with the meta-analysis by Doheim et al. associated the presence of anti-H. pylori IgG with an increased risk of stroke [odds ratio [OR] (95% CI) = 1.43 (1.25–1.46)](), and a retrospective study reported that patients with H. pylori infection had a higher incidence of ischemic stroke than uninfected patients (). However, a few studies have found no association between H. pylori infection and stroke (–). In addition, studies reported controversial results on the association between H. pylori and other neurological pathologies, such as neurodegeneration (–). Metabolic syndrome is well known as the conventional risk factor for atherosclerosis and studies also have shown an association between H. pylori infection and metabolic syndrome (, ).
The mechanism of atherosclerosis pathogenesis is complex and has not been fully defined; however, endothelial dysfunction is believed to play a critical role (). During infection, H. pylori invades and colonizes the gastric mucosal epithelial layer but it remains unknown how H. pylori induces endothelial dysfunction and promotes the development of atherosclerosis in vivo. Exosomes are found in many bodily fluids and play an essential role in cell-to-cell communication by transporting various bioactive constituents such as lipids, proteins, mRNA, and microRNAs (, ). Recent studies have shown that exosomes play a key role in transferring toxic proteins associated with neurodegenerative diseases (). H. pylori virulence factor cytotoxin-associated gene A (CagA) is found in serum-derived exosomes isolated from patients with CagA+H. pylori infection (). The present study was designed to explore that H. pylori infection impair brain endothelial function through exosomes.
To date, the relationship between H. pylori infection and stroke remains controversial and the association between H. pylori infection and intracranial atherosclerosis, especially among young and asymptomatic patients, or those with mild symptoms, in the Chinese population, has not been well investigated. The present study assessed if H. pylori infection is associated with an increased risk of intracranial atherosclerosis.
Materials and Methods
Subjects
Subjects who received a transcranial Doppler (TCD) and 13C-urea breath test (13C-UBT) during their annual physical examination at the Third Xiangya Hospital of Central South University in Changsha, Hunan, China, from March 2012 to March 2017 were enrolled in this study. Individuals with a history of H. pylori eradication, use of any H2-receptor blockers, proton pump inhibitors or antibiotics 3 months prior to the test, age <20 or >80 years, malignancy, thyroid disease, asthma or chronic obstructive pulmonary disease (COPD), hematological disorder or abnormal liver function, or abnormal TCD results who do not have a past head CT result and refused a head CT, were excluded. Subjects were screened and divided into different groups according to the study protocol (Figures 1A,B). Written informed consent was obtained from all subjects prior to participation. The study was conducted according to the principles of the Declaration of Helsinki and was approved by the Clinical Research Ethics Committee of the Third Xiangya Hospital of Central South University, Changsha, China (Approval Number of Ethics Committee: 2019-S241).
Figure 1
Assessment of Intracranial Atherosclerosis
Intracranial carotid artery calcification (ICAC) measured by head CT is shown to be a reliable marker for intracranial atherosclerosis (, ). Subjects with abnormal results on TCD (EME TC8080; Nicolet, Madison, WI, USA) without a past head CT result underwent non-enhanced head CT scanning for artery calcification. TCD examination was performed by an experienced neuroradiologist using a 2 MHz frequency ultrasound probe. Subjects were placed in the supine position after 10 min of rest. Four main acoustic windows, (1) transtemporal, (2) transorbital, (3) submandibular, and (4) suboccipital and blood flow, at various depths within each major branch of the circle of Willis were assessed. Head CT (Siemens, Erlanger, Germany) scans were performed by an experienced neuroradiologist. Bone window CT images (slice thickness 5 mm) through the skull base were used to identify the presence or absence of carotid arterial calcifications in each cavernous carotid (ICAC) artery (). The presence of intracranial atherosclerosis was assessed by an independent expert reader, who was blinded to all clinical laboratory findings and other imaging data.
Detection of H. pylori Infection
After fasting for at least 6 h, subjects received a two-stage 13C-UBT (H20174047, HaiDeRun, Beijing, China) to detect the presence of H. pylori infection. 13C infrared spectrometry was used to analyze exhaled breath samples from each patient. The receiver-operating characteristic curves were used to define the cut-off delta-over-baseline (DOB) values. DOB ≥ 4 () was considered positive and DOB <4 was considered negative.
Other Baseline Measurements
Physical and laboratory test data were collected as described (). Body mass index (BMI) equivalent to weight was divided by square of height (kg/m2). After overnight fasting, blood samples from the antecubital vein were obtained from each patient to measure glucose and serum lipids using a Hitachi 7170S autoanalyzer (Hitachi, Tokyo, Japan). Diabetes was diagnosed among patients with a fasting plasma glucose concentration >6.11 mmol/L or those taking anti-diabetic medicine. Resting blood pressures were obtained with an electronic sphygmomanometer after patients rested for 15 min and three readings from each patient were averaged. Arterial hypertension was diagnosed among patients with a systolic blood pressure (SBP) >130 mmHg, a diastolic blood pressure (DBP) >80 mmHg, or those taking anti-hypertensive medicine.
Cell Culture
Human brain microvascular endothelial cells (HBMECs, ScienCell Research Laboratories, Carlsbad, CA, USA) were cultured in an endothelial cell medium (#1001, ScienCell Research Laboratories, Carlsbad, CA, USA) in a controlled humidified incubator with 5% CO2. To assess the role of H. pylori on brain endothelial cell function, serum exosomes (100 μg/ml) were isolated from subjects with CagA+H. pylori infection or healthy controls, cultured with HBMEC, and collected to measure cell proliferation, migration, and tube formation (Figure 1C).
Exosome Preparation
Serum samples were collected from five patients with CagA+H. pylori infection or five healthy control subjects were combined to isolate an adequate number of exosomes, as previously described (). In brief, exosomes were isolated by successive centrifugation at 4°C at increasing speeds of 2,000 g for 30 min and 12,000 g for 45 min and ultracentrifuged two times at 110,000 g for 2 h. Exosome pellets were re-suspended in a small volume of phosphate-buffered saline (PBS) for further analysis. A transmission electron microscope (TEM, TECNAI G2 Spirit; FEI, Hillsboro, OR, USA), a particle size analyzer (Zetasizer Nano ZS; Malvern, Worcestershire, UK), and western blot analysis were used to examine the morphology, size, distribution, biomarkers (HSP70 and CD9), and CagA protein level of the exosomes.
Entrance of Exosomes Into Endothelial Cells
To determine if the exosomes entered brain endothelial cells, PKH67-labeled (green fluorescent) (Sigma-Aldrich, St. Louis, MO, USA) exosomes were added to HBMEC as described previously (). PKH67-labeled exosomes were incubated with HBMEC for 12 h, and F-actin in the cytoskeleton was stained with Alexa Fluor 555 Phalloidin (A34055; Thermo Fisher, Waltham, MA, USA), and cell nuclei were stained with DAPI fluorescent (D1306; Thermo Fisher, Waltham, MA, USA). Cells were visualized using a confocal laser scanning microscope (Leica TCS SP8, Buffalo Grove, IL, USA).
Endothelial Cell Proliferation, Migration, and Tube Formation Assays
Human brain microvascular endothelial cell proliferation, migration, and tube formation were assessed using a 5-ethynyl-2′-deoxyuridine (EdU) cell proliferation kit (C10337, Invitrogen, Waltham, MA, USA), a chamber transwell system (MCEP24H48, Millipore, Germany), and a Matrigel matrix (356234, Corning Life Sciences, Corning, NY, USA) according to the manufacturer's instructions (). In brief, HBMECs (1 × 104 cells) were treated with exosomes for 24 h and stained with EdU dye and DAPI to assess cell proliferation with a fluorescence microscope. HBMECs (2 × 104 cells) were treated with exosomes for 24 h, plated in the upper transwell chamber for 8 h, fixed, and stained with crystal violet for 10 min. Migrating cells were counted in five random microscopic fields. HBMECs (2 × 104 cells) were treated with exosomes for 24 h and seeded on matrigel (70 μl) for 4 h to assess tube formation under an inverted light microscope. Total capillary tube lengths were quantified using the software Image J. Five independent fields were assessed for each well.
Statistical Analysis
A cross-sectional study was performed to determine the association between intracranial atherosclerosis and H. pylori infection. Categorical variables were presented as percentages (%) and analyzed using chi-square (X2). Quantitative variables were presented as mean ± SE and analyzed using the one-way ANOVA. Adjusted ORs were estimated with logistic regression analysis models. A two-tailed unpaired t-test was used for the analysis of two groups of data with normal distribution and equal variance, and a two-tailed unpaired t-test with Welch correction was used to analyze two groups of data with normal distribution and unequal variance. A Mann-Whitney U test was used for comparisons between two groups of data with abnormal distributions. All data were analyzed using SPSS software (Mac Version 25.0, Chicago, IL, USA), and p < 0.05 was considered statistically significant.
Results
Factors Associated With Intracranial Atherosclerosis
A total of 15,798 subjects received screening using both TCD and a 13C-UBT. After exclusion criteria were applied, 14,084 individuals were included in the study, of whom 9,497 and 4,587 were men and women, respectively (Figure 1B). Subjects were divided into two groups, one including 4,935 patients with intracranial atherosclerosis and the other including 9,149 individuals without intracranial atherosclerosis (Table 1).
Table 1
| Without intracranial atherosclerosis (n = 9,149) | With intracranial atherosclerosis (n = 4,935) | p value | |
|---|---|---|---|
| Female, n (%) | 2,327 (25.4%) | 2,260 (45.7%) | 0.000 |
| H. pylori infection, n (%) | 3,220 (35.1%) | 1,861 (37.7%) | 0.003 |
| Age (years) | 43.45 ± 6.79 | 56.31 ± 8.91 | 0.000 |
| Weight (kg) | 68.80 ± 11.83 | 64.28 ± 11.05 | 0.000 |
| BMI (kg/m2) | 24.89 ± 3.30 | 24.73 ± 3.16 | 0.006 |
| SBP (mmHg)* | 121.81 ± 14.56 | 134.84 ± 19.23 | 0.000 |
| DBP (mmHg)†| 79.37 ± 11.67 | 82.49 ± 12.12 | 0.000 |
| Hypertension, n (%) | 904 (9.9%) | 1,713 (34.7%) | 0.000 |
| Diabetes mellitus, n (%) | 1,029 (11.2%) | 1,299 (26.3%) | 0.000 |
| Smoking, n (%) | 3,749 (43.6%) | 1,484 (31.5%) | 0.000 |
| Alcohol, n (%) | 5,039 (59.7%) | 1,291 (28.8%) | 0.000 |
| Fasting blood sugar (mmol/L) | 5.31 ± 1.28 | 5.72 ± 1.78 | 0.000 |
| Glycated hemoglobin (%) | 5.51 ± 0.75 | 5.79 ± 1.02 | 0.000 |
| Total cholesterol (mmol/L) | 5.11 ± 0.99 | 5.28 ± 1.06 | 0.000 |
| Triglycerides (mmol/L) | 2.11 ± 2.07 | 1.94 ± 1.81 | 0.000 |
| HDL-cholesterol (mmol/L)‡ | 1.43 ± 0.37 | 1.48 ± 0.39 | 0.000 |
| LDL-cholesterol (mmol/L)§ | 2.75 ± 0.84 | 2.94 ± 0.90 | 0.000 |
Baseline characteristics for patients with and without intracranial atherosclerosis.
Data were expressed as mean ± SD or n (%), where appropriate.
SBP, systolic blood pressure;
DBP, diastolic blood pressure;
HDL, high-density lipoprotein;
LDL, low-density lipoprotein.
Patients with intracranial atherosclerosis had a significantly higher rate of H. pylori infection, higher incidence of arterial hypertension and T2DM, higher age, and higher SBP, DBP, fasting blood sugar, glycated hemoglobin, total cholesterol (TC), high-density lipoprotein-cholesterol (HDL-C), and low-density lipoprotein-cholesterol (LDL-C) (Table 1). Patients also had a lower incidence of smoking, alcohol use, body weight, BMI, and triglycerides. There was a significantly higher proportion of women in the intracranial atherosclerosis group than the group without intracranial atherosclerosis (45.7 vs. 25.4%, p < 0.001; Table 1).
Gender Differences in the Prevalence of Intracranial Atherosclerosis
Women had a significantly higher prevalence of intracranial atherosclerosis than men (49.3 vs. 28.2%, p < 0.001; Figure 1B). In addition, female patients with intracranial atherosclerosis had a higher rate of H. pylori infection, higher levels of TC, HDL-C, and LDL-C, a lower incidence of arterial hypertension and T2DM, and lower levels of weight, BMI, fasting blood sugar, SBP, DBP, and triglycerides than men with intracranial atherosclerosis (Table 2).
Table 2
| Male (n = 2,675) | Female (n = 2,260) | p value | |
|---|---|---|---|
| H. pylori infection, n (%) | 905 (33.8%) | 956 (42.3%) | 0.000 |
| Age (years) | 56.50 ± 9.046 | 56.10 ± 8.750 | 0.109 |
| Weight (kg) | 69.998 ± 9.793 | 57.516 ± 8.395 | 0.000 |
| BMI (kg/m2) | 25.273 ± 3.067 | 24.099 ± 3.163 | 0.000 |
| SBP (mmHg)* | 84.69 ± 12.133 | 79.90 ± 11.595 | 0.000 |
| DBP (mmHg)†| 135.66 ± 18.332 | 133.84 ± 20.285 | 0.000 |
| Hypertension, n (%) | 997 (37.3%) | 716 (31.7%) | 0.001 |
| Diabetes mellitus, n (%) | 788 (29.5%) | 511 (22.6%) | 0.000 |
| Smoking, n (%) | 1,448 (59.2%) | 36 (1.6%) | 0.000 |
| Alcohol, n (%) | 1,113 (45.9%) | 178 (8.7%) | 0.000 |
| Fasting blood sugar (mmol/L) | 5.937 ± 2.076 | 5.470 ± 1.33 | 0.000 |
| Glycated hemoglobin (%) | 5.23 ± 1.96 | 5.22 ± 1.51 | 0.865 |
| Total cholesterol (mmol/L) | 5.165 ± 1.055 | 5.429 ± 1.039 | 0.000 |
| Triglycerides (mmol/L) | 2.19 ± 2.157 | 1.642 ± 1.221 | 0.000 |
| HDL-cholesterol (mmol/L)‡ | 1.363 ± 0.342 | 1.624 ± 0.391 | 0.000 |
| LDL-cholesterol (mmol/L)§ | 2.837 ± 0.905 | 3.053 ± 0.888 | 0.000 |
Gender difference analysis in intracranial atherosclerosis patients.
Data were expressed as mean ± SD or n (%), where appropriate.
SBP, systolic blood pressure;
DBP, diastolic blood pressure;
HDL, high-density lipoprotein;
LDL, low-density lipoprotein.
Differences in Age and Gender Among Patients With H. pylori Infection and Intracranial Atherosclerosis
There was a significant difference in the incidence of intracranial atherosclerosis between subjects with and without H. pylori infection (36.6 vs. 34.1%, p < 0.01; Figure 1D). H. pylori-positive female patients had a significantly higher incidence of intracranial atherosclerosis than H. pylori-negative female subjects (53.8 vs. 46.4%, p < 0.001). Incidence of intracranial atherosclerosis was also shown to differ by the age of female subjects with and without H. pylori infection (Figure 1D). However, there was no significant difference in the incidence of intracranial atherosclerosis between male subjects with and without H. pylori infection (Figure 1D). Further analysis showed that after age was adjusted in patients with and without intracranial atherosclerosis, H. pylori infection significantly increased the risk of intracranial atherosclerosis (OR = 2.261, 95% CI = 1.839–2.780, p < 0.001) among women <60 years old, but not among women >60 years old (Table 3, Figure 1D). H. pylori infection, age, BMI, DBP, arterial hypertension, TC, and glycated hemoglobin were independent factors of increased risk of intracranial atherosclerosis among women <60 years of age, while alcohol use and HDL-C were independent factors for decreased risk of intracranial atherosclerosis (Table 3).
Table 3
| Odds ratio (95% CI) | p value | |
|---|---|---|
| H. pylori infection, n (%) | 2.261 (1.839–2.780) | 0.000 |
| Age (years) | 1.262 (1.235–1.289) | 0.000 |
| Alcohol, n (%) | 0.501 (0.275–0.445) | 0.000 |
| BMI (kg/m2) | 1.175 (1.102–1.253) | 0.000 |
| SBP (mmHg)* | 0.969 (0.954–0.984) | 0.000 |
| DBP (mmHg)†| 1.055 (1.043–1.067) | 0.000 |
| Diabetes mellitus, n (%) | 1.450 (1.177–1.786) | 0.000 |
| HDL-cholesterol (mmol/L)‡ | 0.719 (0.540–0.957) | 0.024 |
| Hypertension, n (%) | 2.912 (2.056–4.125) | 0.000 |
| Total cholesterol (mmol/L) | 1.198 (1.054–1.362) | 0.000 |
| Weight (kg) | 0.976 (0.963–0.990) | 0.001 |
Risk factors for intracranial atherosclerosis in female patients under 60 years.
Data were expressed as mean ± SD or n (%), where appropriate.
SBP, systolic blood pressure;
DBP, diastolic blood pressure;
HDL, high-density lipoprotein.
Serum Exosomes From CagA+H. pylori-Infected Patients Inhibited Brain Endothelial Cell Proliferation, Migration, and Tube Formation
Endothelial dysfunction is considered the initial event in the development and progression of atherosclerosis (). Exosomes are found in various body fluids and play an essential role in cell-to-cell communication through the transport of various bioactive constituents, such as proteins, cell-surface receptors, and microRNAs (). A prior study showed that H. pylori virulence factor CagA existed in serum-derived exosomes in patients with CagA+H. pylori infection (). To test whether serum exosomes impacted the cell function of HBMEC, serum exosomes were isolated from human patients with CagA+H. pylori infection or healthy control subjects by ultracentrifugation. TEM, western blotting, and particle size analysis demonstrated the presence of round-shaped vesicles measuring 10–100 nm (Figures 2A–C) in the serum exosomes. Western blotting demonstrated that serum exosomes contained CagA protein (Figure 2B). Fluorescence microscopy showed that PKH67-labeled CagA-containing exosomes were internalized by HBMEC (Figure 2D). Treatment with CagA-containing exosomes significantly inhibited HBMEC migration, tube formation, and proliferation in vitro (Figures 2E–G, e–g).
Figure 2
Discussion
The present study demonstrated that H. pylori infection is common in China, with a rate of 38.8% for women and 34.8% for men (Supplementary Figure 1). After adjusting for atherosclerosis risk factors, H. pylori infection was shown to be an independent risk factor for intracranial atherosclerosis, especially in women ≤ 60 years. Serum exosomes from patients with CagA+H. pylori infection significantly decreased brain endothelial cell migration, tube formation, and proliferation in vitro.
Atherosclerosis, a chronic syndrome leading to the thickening and hardening of artery walls, is a major cause of morbidity and mortality of stroke worldwide (). Evidence suggests that various infectious agents, such as H. pylori, contribute to atherosclerosis () and H. pylori is implicated as a microbial risk factor for stroke (, ). However, other studies show that there is no association between H. pylori infection and stroke, suggesting that H. pylori may not be a risk factor for microcirculatory damage in the brain (, , ). Thus, the relationship between H. pylori infection and stroke remains controversial. This may be because of study-specific differences in sample size, population, design, and H. pylori prevalence. The present study showed a significant association between H. pylori infection and intracranial atherosclerosis, especially in women ≤ 60 years of age.
Cytotoxin-associated gene A is considered the most important H. pylori virulence factor (). Many studies show that H. pylori, especially CagA+H. pylori infection, contributes substantially to the risk of atherosclerosis or other cardiovascular diseases (, ). The current study also showed that H. pylori infection increased the risk of intracranial atherosclerosis. Serum exosomes from patients with CagA+H. pylori infection significantly decreased brain endothelial function in vitro. However, no significant differences were seen in the risk of intracranial atherosclerosis between individuals with CagA+ and CagA−H. pylori infections. This may be due to a lack of CagA-specific testing and warrants further analysis.
The underlying mechanism for the pathogenesis of H. pylori-associated atherosclerosis is complex and not well understood. Endothelial dysfunction is the initial event and plays a critical role in atherosclerosis (). Evidence suggests that H. pylori infection could lead to increased homocysteine as a result of reduced folate and/or poor B12 absorption (, 44). Homocysteine inhibits the secretion of nitric oxide from endothelial cells, which facilitates platelet aggregation and vasoconstriction and causes endothelial damage (45, 46). Previous studies define the relationship between H. pylori infection and endothelial dysfunction (, 47–49). In the present study, serum exosomes from patients with CagA+H. pylori infection significantly limited HBMEC function in vitro. These data suggested that the risk of intracranial atherosclerosis following H. pylori infection may be due to endothelial dysfunction. However, further studies are needed to determine if H. pylori infection enhances the development and/or progression of intracranial atherosclerosis via endothelial dysfunction.
Arterial hypertension, age, T2DM, and metabolic syndrome are identified as independent risk factors for intracranial atherosclerosis (, , ), and are thought to be associated with increased prevalence and severity of diseases. The present study demonstrated that patients with intracranial atherosclerosis had metabolic syndrome and had a significantly higher incidence of arterial hypertension and T2DM and higher age than those without intracranial atherosclerosis. These data are consistent with previous observations. The current study showed that patients with intracranial atherosclerosis had a lower incidence of smoking, use of alcohol, lower body weight, and BMI than those in the control group. The higher proportion of women in the intracranial atherosclerosis group may explain this difference. A multitude of investigations reports a link between H. pylori infection and metabolic syndrome (, ). In the present study, the incidence of intracranial atherosclerosis and the levels of LDL-C, TC, and SBP in patients with H. pylori infection were significantly higher than those without H. pylori infection (Supplementary Table 1). These current data showed the association between atherosclerosis and metabolic syndrome and between H. pylori infection and metabolic syndrome or intracranial atherosclerosis. These data are consistent with previous observations that H. pylori infection induces a metabolic disorder of blood lipids and a higher risk of atherosclerosis (50–52). Thus, it is speculated that H. pylori may induce metabolic syndrome and endothelial dysfunction, and promote the development and progression of intracranial atherosclerosis.
Gender differences exist in many cerebrovascular diseases. It is well known that dementia risk and severity are significantly higher in women than men (53–55). The incidence of subarachnoid hemorrhage (SAH) and aneurysms are higher in women than men due to hormonal differences, intrinsic wall weaknesses, and hemodynamic forces on intracranial arteries (56, 57). Women also have a higher overall lifetime risk of stroke than men (58). In the present study, women had a significantly higher prevalence of intracranial atherosclerosis than men and the intracranial atherosclerosis group had a higher proportion of women than the control group. These data were consistent with previous observations on gender differences in cerebrovascular diseases. Some studies show that H. pylori infection is greater in women than men, as indicated by higher bacterial load (59), other studies have shown no significant differences by sex (60, 61). In the current study, H. pylori infection rate was significantly higher in women than men. It is speculated that H. pylori infection acting as an independent risk factor for intracranial atherosclerosis in women may due to higher H. pylori infection rate and the increased H. pylori load in women.
Evidence also indicates that neurological diseases improve through the eradication of H. pylori infection (62–67). Patients with Parkinson's disease for whom H. pylori has been eradicated have reduced motor fluctuation (62), improved L-dopa absorption (63), and slower disease progression (64). Some studies observed an improvement in cognitive and functional status (65) and a decreased disease progression (66) in Alzheimer's disease patients after the eradication of H. pylori. Another study showed that 6 months after eradication of H. pylori in ischemic stroke patients, plasma levels of TC, LDL-C, fibrinogen, and IL-8 were significantly lower than those seen in H. pylori-infected stroke patients and controls (67). Future studies are needed to investigate a potential association between H. pylori-eradication and intracranial atherosclerosis.
There were a few limitations in this study. The study cohort was enrolled from one center with individuals of the same ethnicity. In addition, findings could not elucidate the long-term influence of H. pylori infection on intracranial atherosclerosis because of a lack of follow-up data. Future prospective studies are needed to determine if significant gender differences are observed over time.
Conclusion
In summary, H. pylori infection acted as an independent risk factor for intracranial atherosclerosis in women ≤ 60 years of age but not among older women or men.
Funding
This work was supported by grants from Fundamental Research Funds for the Central Universities of Central South University (Grant No. 2019zzts352) and the National Innovative Training Program of China (Grant No. 201310533059).
Publisher's Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Statements
Data availability statement
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
Ethics statement
The studies involving human participants were reviewed and approved by the Clinical Research Ethics Committee of the Third Xiangya Hospital of Central South University, Changsha, China (Approval Number of Ethics Committee: 2019-S241). The patients/participants provided their written informed consent to participate in this study.
Author contributions
XX and ZC were in charge of the entire project and revised the draft of the manuscript. YG collected the data and wrote the manuscript. CX and LZ did the statistics. All authors contributed to the article and approved the submitted version.
Acknowledgments
The authors wish to thank the staff in the Department of Health Management, the Third Xiangya Hospital of Central South University, Changsha, Hunan, China for their assistance on database maintenance and protection.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as apotential conflict of interest.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm.2021.819315/full#supplementary-material
Supplementary Table 1Baseline characteristics for subjects with and without H. pylori Infection.
Supplementary Figure 1Gender difference of H. pylori infection.
References
1.
FitzGeraldRSmithSM. An overview of Helicobacter pylori infection. Methods Mol Biol. (2021) 2283:1–14. 10.1007/978-1-0716-1302-3_1
2.
Pinto-RibeiroIFerreiraRMBatalhaSHlaingTWongSICarneiroFet al. Helicobacter pylori vacGenotypes A in chronic gastritis and gastric carcinoma patients from Macau, China. Toxins. (2016) 8:142. 10.3390/toxins8050142
3.
MentisALehoursP. M Fégraud. Epidemiology and diagnosis of Helicobacter pylori infection. Helicobacter. (2015) 20Suppl 1:1–7. 10.1111/hel.12250
4.
EusebiLHZagariRMBazzoliF. Epidemiology of Helicobacter pylori infection. Helicobacter. (2014) 19Suppl 1:1–5. 10.1111/hel.12165
5.
KuipersEJ. Helicobacter pylori and the risk and management of associated diseases: gastritis, ulcer disease, atrophic gastritis and gastric cancer. Aliment Pharmacol Ther. (1997) 11Suppl 1:71–88. 10.1046/j.1365-2036.11.s1.5.x
6.
TanHJGohKL. Extragastrointestinal manifestations of Helicobacter pylori infection: facts or myth? A critical review. Dig J Dis. (2012) 13:342–9. 10.1111/j.1751-2980.2012.00599.x
7.
PellicanoRIaniroGFagooneeSSettanniCRGasbarriniA. Review: extragastric diseases and Helicobacter pylori.Helicobacter. (2020) 25Suppl 1:e12741. 10.1111/hel.12741
8.
QureshiAICaplanLR. Intracranial atherosclerosis. Lancet. (2014) 383:984–98. 10.1016/s0140-6736(13)61088-0
9.
BanerjeeCChimowitzMI. Stroke caused by Atherosclerosis of the major intracranial arteries. Circ Res. (2017) 120:502–13. 10.1161/CIRCRESAHA.116.308441
10.
RitzKDenswilNPStamOCvan JLieshoutJDaemenMJ. Cause and mechanisms of intracranial atherosclerosis. Circulation. (2014) 130:1407–14. 10.1161/circulationaha.114.011147
11.
López-CancioEGalánADoradoLJiménezMHernándezMMillánMet al. Biological signatures of asymptomatic extra- and intracranial atherosclerosis: the Barcelona-AsIA (Asymptomatic Intracranial Atherosclerosis) study. Stroke. (2012) 43:2712–9. 10.1161/strokeaha.112.661702
12.
LibbyPRidkerPMHanssonGK. Progress and challenges in translating the biology of atherosclerosis. Nature. (2011) 473:317–25. 10.1038/nature10146
13.
LiBXiaYHuB. Infection and atherosclerosis: TLR-dependent pathways. Cell Mol Life Sci. (2020) 77:2751–69. 10.1007/s00018-020-03453-7
14.
Shindler-ItskovitchTChodickGShalevVMuhsenK. Helicobacter pylori infection and prevalence of stroke. Helicobacter. (2019) 24:e12553. 10.1111/hel.12553
15.
DoheimMFAltaweelAAElgendyMGElshanbaryAADibasMAliAet al. Association between Helicobacter pylori infection and stroke: a meta-analysis of 273,135 patients. Neurol J. (2021) 268:3238–48. 10.1007/s00415-020-09933-x
16.
HuangWSTsengCHLinCLTsaiCHKaoCH. Helicobacter pylori infection increases subsequent ischemic stroke risk: a nationwide population-based retrospective cohort study. QJM. (2014) 107:969–75. 10.1093/qjmed/hcu117
17.
JiangJChenYShiJSongCZhangJWangK. Population attributable burden of Helicobacter pylori-related gastric cancer, coronary heart disease, and ischemic stroke in China. Eur Clin J Microbiol Infect Dis. (2017) 36:199–212. 10.1007/s10096-016-2810-x
18.
YuMZhangYYangZDingJXieCLuN. Association between Helicobacter pylori infection and stroke: a meta-analysis of prospective observational studies. Stroke J Cerebrovasc Dis. (2014) 23:2233–9. 10.1016/j.jstrokecerebrovasdis.2014.04.020
19.
HeuschmannPUNeureiterDGessleinMCraiovanBMaassMFallerGet al. Association between infection with Helicobacter pylori and Chlamydia pneumoniae and risk of ischemic stroke subtypes: results from a population-based case-control study. Stroke. (2001) 32:2253–8. 10.1161/hs1001.097096
20.
YangXGaoYZhaoXTangYSuY. Chronic Helicobacter pylori infection and ischemic stroke subtypes. Neurol Res. (2011) 33:467–72. 10.1179/016164111x13007856083963
21.
BeydounMABeydounHAElbejjaniMDoreGAZondermanAB. Helicobacter pylori seropositivity and its association with incident all-cause and Alzheimer's disease dementia in large national surveys. Alzheimers Dement. (2018) 14:1148–58. 10.1016/j.jalz.2018.04.009
22.
FuPGaoMKYungKL. Association of intestinal disorders with Parkinson's disease and Alzheimer's disease: a systematic review and meta-analysis. ACS Chem Neurosci. (2020) 11:395–405. 10.1021/acschemneuro.9b00607
23.
FaniLWoltersFJIkramMKBrunoMJHofmanAKoudstaalPJet al. Helicobacter pylori and the risk of dementia: a population-based study. Alzheimers Dement. (2018) 14:1377–82. 10.1016/j.jalz.2018.05.005
24.
LimSHKimNKwonJWKimSEBaikGHLeeJYet al. Positive association between Helicobacter pylori infection and metabolic syndrome in a Korean population: a multicenter nationwide study. Dig Dis Sci. (2019) 64:2219–30. 10.1007/s10620-019-05544-3
25.
YuYCaiJSongZWangJWuL. Association of Helicobacter pylori infection with metabolic syndrome in aged Chinese females. Exp Ther Med. (2019) 17:4403–8. 10.3892/etm.2019.7509
26.
GimbroneMAJr.GarcG-C. Endothelial cell dysfunction and the pathobiology of atherosclerosis. Circ Res. (2016) 118:620–36. 10.1161/circresaha.115.306301
27.
VuNBNguyenHTPalumboRPellicanoRFagooneeSPhamPV. Stem cell-derived exosomes for wound healing: current status and promising directions. Minerva Med. (2021) 112:384–400. 10.23736/s0026-4806.20.07205-5
28.
ZhangLYuD. Exosomes in cancer development, metastasis, and immunity. Biochim Biophys Acta Rev Cancer. (2019) 1871:455–68. 10.1016/j.bbcan.2019.04.004
29.
BellinghamSAGuoBBColemanBMHillAF. Exosomes: vehicles for the transfer of toxic proteins associated with neurodegenerative diseases?Front Physiol. (2012) 3:124. 10.3389/fphys.2012.00124
30.
XiaXZhangLChiJLiHLiuXHuTet al. Helicobacter pylori infection impairs endothelial function through an exosome-mediated mechanism. Am J Heart Assoc. (2020) 9:e014120. 10.1161/jaha.119.014120
31.
BosDPortegiesML.vanAder LugtBosMJKoudstaalPJHofmanAet al. Intracranial carotid artery atherosclerosis and the risk of stroke in whites: the Rotterdam Study. Neurol JAMA. (2014) 71:405–11. 10.1001/jamaneurol.2013.6223
32.
ErbaySHanRAftabMZouKHPolakJFBhadeliaRA. Is intracranial atherosclerosis an independent risk factor for cerebral atrophy? A retrospective evaluation. Neurol BMC. (2008) 8:51. 10.1186/1471-2377-8-51
33.
GuLLiSHeYChenYJiangYPengYet al. Bismuth, rabeprazole, amoxicillin, and doxycycline as first-line Helicobacter pylori therapy in clinical practice: a pilot study. Helicobacter. (2019) 24:e12594. 10.1111/hel.12594
34.
DaiHWangWChenRChenZLuYYuanH. Lipid accumulation product is a powerful tool to predict non-alcoholic fatty liver disease in Chinese adults. Nutr Metab. (2017) 14:49. 10.1186/s12986-017-0206-2
35.
ThéryCAmigorenaSRaposoGClaytonA. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol. (2006) 3:22. 10.1002/0471143030.cb0322s30
36.
EgermayerP. The role of infectious agents in pulmonary and systemic vascular disease. Expert Opin Pharmacother. (2001) 2:1093–7. 10.1517/14656566.2.7.1093
37.
VijayanMReddyPH. Stroke, vascular dementia, and alzheimer's disease: molecular links. Alzheimers J Dis. (2016) 54:427–43. 10.3233/jad-160527
38.
CaveDR. Transmission and epidemiology of Helicobacter pylori. Am Med J. (1996) 100:12S−17S; discussion 17S-18S. 10.1016/s0002-9343(96)80224-5
39.
JangSHLeeHKimJSParkHJJeongSMLeeSHet al. Association between Helicobacter pylori infection and cerebral small vessel disease. Korean Fam J Med. (2015) 36:227–32. 10.4082/kjfm.2015.36.5.227
40.
KalaliB.Mej RÃas-LuqueJavaheriAGerhardM. H pylori virulence factors: influence on immune system and pathology. Mediators Inflamm. (2014) 2014:426309. 10.1155/2014/426309
41.
De BastianiRGabrielliMUbaldiEBenedettoESannaGCottoneCet al. High prevalence of Cag-positive A H. pylori strains in ischemic stroke: a primary care multicenter study. Helicobacter. (2008) 13:274–7. 10.1111/j.1523-5378.2008.00610.x
42.
PietroiustiADiomediMSilvestriniMCupiniLMLuzziI.Gomez MJ-Miguelet al. Cytotoxin-associated gene-A-positive Helicobacter pylori strains are associated with atherosclerotic stroke. Circulation. (2002) 106:580–4. 10.1161/01.cir.0000023894.10871.2f
43.
MarkleHV. Coronary artery disease associated with Helicobacter pylori infection is at least partially due to inadequate folate status. Med Hypotheses. (1997) 49:289–92. 10.1016/s0306-9877(97)90191-2
44.
SungJJSandersonJE. Hyperhomocysteinaemia, Helicobacter pylori, and coronary heart disease. Heart. (1996) 76:305–7. 10.1136/hrt.76.4.305
45.
StamlerJSOsborneJAJarakiORabbaniLEMullinsMSingelDet al. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. Clin J Invest. (1993) 91:308–18. 10.1172/jci116187
46.
HarkerLASlichterSJScottCRRossR. Homocystinemia. Vascular injury and arterial thrombosis. Engl N Med J. (1974) 291:537–43. 10.1056/nejm197409122911101
47.
BlumATamirSMualemK.Ben RS-ShushanKeinan L-BokerParitskyM. Endothelial dysfunction is reversible in Helicobacter pylori-positive subjects. Am Med J. (2011) 124:1171–4. 10.1016/j.amjmed.2011.08.015
48.
TobinNPHenehanGTMurphyRPAthertonJCGuinanAFKerriganSWet al. Helicobacter pylori-induced inhibition of vascular endothelial cell functions: a role for VacA-dependent nitric oxide reduction. Am Physiol J Heart Circ Physiol. (2008) 295:H1403–13. 10.1152/ajpheart.00240.2008
49.
OshimaTOzonoRYanoYOishiYTeragawaHHigashiYet al. Association of Helicobacter pylori infection with systemic inflammation and endothelial dysfunction in healthy male subjects. Am J Coll Cardiol. (2005) 45:1219–22. 10.1016/j.jacc.2005.01.019
50.
Nam SY RyuKHParkBJParkS. Effects of Helicobacter pylori infection and its eradication on lipid profiles and cardiovascular diseases. Helicobacter. (2015) 20:125–32. 10.1111/hel.12182
51.
ShimamotoTYamamichiNGondoKTakahashiYTakeuchiCWadaRet al. The association of Helicobacter pylori infection with serum lipid profiles: an evaluation based on a combination of meta-analysis and a propensity score-based observational approach. PLoS ONE. (2020) 15:e0234433. 10.1371/journal.pone.0234433
52.
SungKCRhee EJ RyuSHBeckSH. Prevalence of Helicobacter pylori infection and its association with cardiovascular risk factors in Korean adults. Int Cardiol J. (2005) 102:411–7. 10.1016/j.ijcard.2004.05.040
53.
van den HeuvelDMAdmiraal-BehloulFten VDamHOlofsenHBollenELMurrayHMet al. Different progression rates for deep white matter hyperintensities in elderly men and women. Neurology. (2004) 63:1699–701. 10.1212/01.wnl.0000143058.40388.44
54.
Gallart-PalauXLeeBSAdavSSQianJSerraAParkJEet al. Gender differences in white matter pathology and mitochondrial dysfunction in Alzheimer's disease with cerebrovascular disease. Mol Brain. (2016) 9:27. 10.1186/s13041-016-0205-7
55.
de LeeuwFEde JGrootCAchtenEOudkerkMRamosLMHeijboerRet al. Prevalence of cerebral white matter lesions in elderly people: a population based magnetic resonance imaging study. The Rotterdam Scan Study. Neurol J Neurosurg Psychiatry. (2001) 70:9–14. 10.1136/jnnp.70.1.9
56.
BrismanJLSongJKNewellDW. Cerebral aneurysms. Engl N Med J. (2006) 355:928–39. 10.1056/NEJMra052760
57.
MhurchuCNAndersonCJamrozikKHankeyGDunbabinD. Hormonal factors and risk of aneurysmal subarachnoid hemorrhage: an international population-based, case-control study. Stroke. (2001) 32:606–12. 10.1161/01.str.32.3.606
58.
ReevesMJBushnellCDHowardGGarganoJWDuncanPWLynchGet al. Sex differences in stroke: epidemiology, clinical presentation, medical care, and outcomes. Lancet Neurol. (2008) 7:915–26. 10.1016/s1474-4422(08)70193-5
59.
MoshkowitzMHorowitzN. Beit A-Or, Halpern Z, Santo E. Gender-associated differences in urea breath test for Helicobacter pylori infection referrals and results among dyspeptic patients. World Gastrointest J Pathophysiol. (2012) 3:80–4. 10.4291/wjgp.v3.i3.80
60.
van BlankensteinMvan AVuurenJLoomanCWOuwendijkMKuipersEJ. The prevalence of Helicobacter pylori infection in the Netherlands. Scand Gastroenterol J. (2013) 48:794–800. 10.3109/00365521.2013.799221
61.
VilaichoneRKMahachaiVShiotaSUchidaT.Ratanachu T-ekTsheringLet al. Extremely high prevalence of Helicobacter pylori infection in Bhutan. World Gastroenterol J. (2013) 19:2806–10. 10.3748/wjg.v19.i18.2806
62.
LeeWYYoonWTShinHYJeonSHRheePL. Helicobacter pylori infection and motor fluctuations in patients with Parkinson's disease. Mov Disord. (2008) 23:1696–700. 10.1002/mds.22190
63.
LyteM. Microbial endocrinology as a basis for improved L-DO bioavailability Pin A Parkinson's patients treated for Helicobacter pylori.Med Hypotheses. (2010) 74:895–7. 10.1016/j.mehy.2009.11.001
64.
DobbsSMDobbsRJWellerCCharlettABjarnasonITLawsonAJet al. Differential effect of Helicobacter pylori eradication on time-trends in brady/hypokinesia and rigidity in idiopathic parkinsonism. Helicobacter. (2010) 15:279–94. 10.1111/j.1523-5378.2010.00768.x
65.
KountourasJBozikiMGavalasEZavosCGrigoriadisNDeretziGet al. Eradication of Helicobacter pylori may be beneficial in the management of Alzheimer's disease. Neurol J. (2009) 256:758–67. 10.1007/s00415-009-5011-z
66.
ChangYPChiuGFKuoFCLaiCLYangYHHuHMet al. Eradication of Helicobacter pylori is associated with the progression of dementia: population a-based study. Gastroenterol Res Pract. (2013) 2013:175729. 10.1155/2013/175729
67.
MajkaJ.RTógKonturekPCKonturekSJBiela WńskiKowalskyMet al. Influence of chronic Helicobacter pylori infection on ischemic cerebral stroke risk factors. Med Sci Monit. (2002) 8:Cr675–84.
Summary
Keywords
Helicobacter pylori, intracranial atherosclerosis, gender difference, age difference, endothelial dysfunction
Citation
Guo Y, Xu C, Zhang L, Chen Z and Xia X (2022) Helicobacter pylori Infection Acts as an Independent Risk Factor for Intracranial Atherosclerosis in Women Less Than 60 Years Old. Front. Cardiovasc. Med. 8:819315. doi: 10.3389/fcvm.2021.819315
Received
21 November 2021
Accepted
13 December 2021
Published
11 January 2022
Volume
8 - 2021
Edited by
Rudolph Schutte, Anglia Ruskin University, United Kingdom
Reviewed by
Rinaldo Pellicano, Molinette Hospital, Italy; Michael Doulberis, Aarau Cantonal Hospital, Switzerland
Updates
Copyright
© 2022 Guo, Xu, Zhang, Chen and Xia.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Xiujuan Xia xiaxiujuan2007@163.comZhiheng Chen 873127193@qq.com
This article was submitted to Atherosclerosis and Vascular Medicine, a section of the journal Frontiers in Cardiovascular Medicine
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.